Evaluating full-body imaging technology for skin disease detection
DermaFlow Alpha - Multi-modal Quantitative Imaging of the Skin
HJN Sverige AB/Neko Health · NCT06989216
This study is testing a new full-body imaging technology to see if it can help doctors better detect and monitor skin diseases like skin cancer and eczema.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 8000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | HJN Sverige AB/Neko Health (industry) |
| Locations | 3 sites (Stockholm and 2 other locations) |
| Trial ID | NCT06989216 on ClinicalTrials.gov |
What this trial studies
This clinical investigation assesses the feasibility of using full-body multi-modal imaging technology for screening and monitoring various skin diseases, including skin cancer and atopic dermatitis. Participants undergo a primary care visit where high-resolution 2D and 3D images, along with thermal images, are captured to evaluate skin lesions. The study aims to correlate these imaging results with clinical diagnoses and improve early detection methods in primary care settings.
Who should consider this trial
Good fit: Ideal candidates are adult patients visiting primary care facilities who can provide informed consent.
Not a fit: Patients with cognitive impairments or severe disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance early detection and monitoring of skin diseases, leading to better patient outcomes.
How similar studies have performed: While the use of multi-modal imaging is gaining traction, this specific approach is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation. * Patients with signed informed consent Exclusion criteria: * Cognitive impairment * Patients unable to understand the oral and written study information in Swedish or English * Other severe disorder or terminal disease * Patients unable to provide an informed consent * Patients not able to keep balance, while standing up with closed eyes, without any aid * Claustrophobic patients
Where this trial is running
Stockholm and 2 other locations
- Atrium Health Care Centre — Stockholm, Sweden (RECRUITING)
- Neko Health Centre Regeringsgatan — Stockholm, Sweden (RECRUITING)
- Neko Health Centre Sibyllegatan — Stockholm, Sweden (RECRUITING)
Study contacts
- Principal investigator: Andreea Valdman, MD — Neko Health AB
- Study coordinator: Mattias Windå, MSc
- Email: mattias@nekohealth.com
- Phone: 0703169040
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Skin Cancer, Skin Diseases, Atopic Dermatitis, Psoriasis, Raynaud Disease, Diabetic Foot, Peripheral Arterial Disease